KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Inventory (2016 - 2025)

Opko Health's Inventory history spans 16 years, with the latest figure at $65.8 million for Q4 2025.

  • For Q4 2025, Inventory rose 15.89% year-over-year to $65.8 million; the TTM value through Dec 2025 reached $65.8 million, up 15.89%, while the annual FY2025 figure was $65.8 million, 15.89% up from the prior year.
  • Inventory reached $65.8 million in Q4 2025 per OPK's latest filing, up from $65.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $159.1 million in Q1 2021 to a low of $56.8 million in Q4 2024.
  • Average Inventory over 5 years is $80.1 million, with a median of $70.2 million recorded in 2022.
  • Peak YoY movement for Inventory: surged 84.64% in 2021, then plummeted 38.16% in 2022.
  • A 5-year view of Inventory shows it stood at $86.5 million in 2021, then dropped by 14.38% to $74.1 million in 2022, then decreased by 11.29% to $65.7 million in 2023, then fell by 13.55% to $56.8 million in 2024, then rose by 15.89% to $65.8 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's Inventory are $65.8 million (Q4 2025), $65.0 million (Q3 2025), and $66.3 million (Q2 2025).